Regulatory activity over the past week reflected steady committee throughput in Europe, a targeted oncology decision in the USA, and a cluster of safety and supply updates in the UK, Canada and ...
US pharma company Esperion Therapeutics has entered into an agreement to acquire Corstasis Therapeutics, a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient ...
Priovant Therapeutics today announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for brepocitinib for the treatment of dermatomyositis (DM) and has ...
UK-based 4basebio, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, says it has promoted Christine Wolosin to chief commercial officer.
Chinese drug developer Hua Medicine (HKEX: 2552) has won marketing approval in Hong Kong for Myhomsis (dorzagliatin), a first-in-class glucokinase activator for adults with Type 2 diabetes.
Germany’s Secarna Pharmaceuticals, which is focused on the discovery and development of best-in-class oligonucleotide therapeutics today announced the expansion of the existing scientific and ...
Scotland-based contract development and manufacturing organisation (CDMO) Symbiosis Services, a specialist in the GMP ...
US pharma major Merck (NYSE: MRK) has reported a Phase III success for Welireg (belzutifan) plus Keytruda (pembrolizumab) as ...
French biotech OSE Immunotherapeutics (Euronext Paris: OSE) is accelerating a strategic reset, pausing development of OSE-230 and discontinuing certain early research programs to concentrate capital ...
Danish vaccine maker Bavarian Nordic announced today, that the board of directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal reasons.
United Therapeutics has announced that its long-term pivotal Phase III ADVANCE OUTCOMES study met its primary endpoint, with ralinepag reducing the risk of a clinical worsening event by 55% compared ...
California-based immunotherapy company 3T Biosciences has appointed Rebeca Villarreal-Barragan as head of clinical operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results